PMID- 22685654
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20120823
LR  - 20230502
IS  - 2090-2158 (Electronic)
IS  - 2090-214X (Print)
VI  - 2012
DP  - 2012
TI  - Is There a Role for Mammalian Target of Rapamycin Inhibition in Renal Failure due 
      to Mesangioproliferative Nephrotic Syndrome?
PG  - 427060
LID - 10.1155/2012/427060 [doi]
LID - 427060
AB  - Primary glomerulonephritis stands as the third most important cause of end-stage 
      renal disease, suggesting that appropriate treatment may not be as effective as 
      intended to be. Moreover, proteinuria, the hallmark of glomerular damage and a 
      prognostic marker of renal damage progression, is frequently resistant to 
      thorough control. In addition, proteinuria may be the common end pathway in which 
      different pathogenetic mechanisms may converge. This explains why 
      immunosuppressive and nonimmunosuppressive approaches are partly not sufficient 
      to halt disease progression. One of the commonest causes of primary 
      glomerulonephritis is mesangioproliferative glomerulonephritis. Among the 
      triggered intracellular pathways involved in mesangial cell proliferation, the 
      mammalian target of rapamycin (mTOR) plays a critical role in cell growth, in 
      turn regulated by many cytokines, disbalanced by the altered glomerulopathy 
      itself. However, when inhibition of mTOR was studied in rodents and in humans 
      with primary glomerulonephritis the results were contradictory. In light of these 
      controversial data, we propose an explanation for these results, to dilucidate 
      under which circumstances mTOR inhibition should be considered to treat 
      glomerular proteinuria and finally to propose mTOR inhibitors to be prospectively 
      assessed in clinical trials in patients with primary mesangioproliferative 
      glomerulonephritis, for which a satisfactory standard immunosuppressive regimen 
      is still pending.
FAU - Trimarchi, Hernan
AU  - Trimarchi H
AD  - Division of Nephrology, Department of Medicine, Hospital Britanico de Buenos 
      Aires, 1280 Buenos Aires, Argentina.
FAU - Forrester, Mariano
AU  - Forrester M
FAU - Lombi, Fernando
AU  - Lombi F
FAU - Pomeranz, Vanesa
AU  - Pomeranz V
FAU - Iriarte, Romina
AU  - Iriarte R
FAU - Rana, Maria Soledad
AU  - Rana MS
FAU - Young, Pablo
AU  - Young P
LA  - eng
PT  - Journal Article
DEP - 20120521
PL  - United States
TA  - Int J Nephrol
JT  - International journal of nephrology
JID - 101546753
PMC - PMC3364552
EDAT- 2012/06/12 06:00
MHDA- 2012/06/12 06:01
PMCR- 2012/05/21
CRDT- 2012/06/12 06:00
PHST- 2012/01/05 00:00 [received]
PHST- 2012/02/16 00:00 [revised]
PHST- 2012/03/22 00:00 [accepted]
PHST- 2012/06/12 06:00 [entrez]
PHST- 2012/06/12 06:00 [pubmed]
PHST- 2012/06/12 06:01 [medline]
PHST- 2012/05/21 00:00 [pmc-release]
AID - 10.1155/2012/427060 [doi]
PST - ppublish
SO  - Int J Nephrol. 2012;2012:427060. doi: 10.1155/2012/427060. Epub 2012 May 21.